Clinical trials: High Cardiovascular Risk Patients
Systemic Right Ventricle, Tricuspid Regurgitation
Percutaneous Edge To Edge Repair for the Treatment of Severe Tricuspid Valve Regurgitation in High-surgical Risk Patients With Systemic Right Ventricle : a Multicentric French Cohort (PETER-TRESRIV)
Our study is about to follow adult congenital patients, known with systemic right ventricle (mostly correct transposition of the great arteries ou congenitally corrected transposition fo the great arteries) and systemic valve…
- Conditions
- Systemic Right Ventricle, Tricuspid Regurgitation, Congenital Heart Disease
- Trial name
- PETER-TRESRIV (NCT05052177)
- Testing
- Edge to edge repair in systemic tricuspid valve regurgitation
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University of Bordeaux
Plasma Cell Leukemia in Remission, Plasma Cell Myeloma
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
This phase I/II trial studies the side effects and best dose of melphalan and total marrow irradiation and how well they work with autologous stem cell transplantation in treating patients with high-risk multiple myeloma.
- Trial name
- NCT03100877
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim
- Where
- United States
- Sponsor
- City of Hope Medical Center
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and total marrow irradiation before a donor…
- Conditions
- Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
- Trial name
- NCT01163357
- Testing
- bortezomib, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Coronary Artery Disease, Heart Failure
PIONEER Trial:Hemodynamic Support With ECMO and IABP in Elective Complex High-risk PCI
To determine whether hemodynamic support combining VA-ECMO with IABP could mitigate the rates of Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs), compared with IABP support alone, in patients undergoing elective…
- Trial name
- NCT04045873
- Testing
- extracorporeal membrane oxygenation
- Volunteers
- 306 people
- Sponsor
- Xijing Hospital
Coronary Artery Disease, HMG-CoA Reductase Inhibitor Toxicity
Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients
The present study constitutes a study examining the effect of atorvastatin on vascular function in high cardiovascular risk patients.
- Conditions
- Coronary Artery Disease, HMG-CoA Reductase Inhibitor Toxicity, Atherosclerosis, Oxidative Stress
- Trial name
- NCT01013103
- Testing
- Atorvastatin, high vs low dose
- Where
- Greece
- Volunteers
- 72 people
- Sponsor
- Hippocration General Hospital
Hypertension
Real-World Validation for Less-Disturbing Ambulatory Blood Pressure Monitoring (ABPM) in Malaysia Using Huawei Wearables
Background: Ambulatory Blood Pressure Monitoring (ABPM) is the gold standard for diagnosing high blood pressure (hypertension) because it tracks blood pressure continuously across day and night.
- Trial name
- Huawei-SunU2 (NCT07790978)
- Where
- Malaysia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sunway University
Coronary Arterial Disease (CAD), Coronary Arteriosclerosis
PRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging tEchniques
This is a combined cohort study with retrospectively and prospectively enrolled coronary artery disease (CAD) patients. All the patients will undergo clinical follow-up for up to 5 years, and repeat coronary CTA will be conducted…
- Trial name
- PRACTICE (NCT06794684)
- Where
- 2 sites in China
- Volunteers
- 50,000 people
- Sponsor
- Ruijin Hospital
Coronary Heart Disease
A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
The purpose of this study is to evaluate the safety and cholesterol lowering effects of MPSK3169A when given as subcutaneous (SC) injections over a 24-week period to patients with a high risk of cardiovascular events and LDL-c…
- Trial name
- NCT01609140
- Testing
- MPSK3169A
- Where
- 73 sites in United States, Canada and 7 more
- Volunteers
- 248 people
- Sponsor
- Genentech, Inc.
Pulmonary Embolism With Acute Cor Pulmonale
Catheter-directed Thrombectomy in High and Intermediate-high Risk Pulmonary Embolism
Pulmonary embolism is one of the leading causes of cardiovascular death. Pulmonary embolism may be life-threatening condition with an estimated 30-day mortality rate about 10-30%.
- Trial name
- CATH-PE (NCT04473560)
- Testing
- Catheter-directed thrombectomy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Poznan University of Medical Sciences
Intubation, Cardiovascular Surgical Procedure
Reducing Reintubation Risk in High-Risk Cardiac Surgery Patients With High-Flow Nasal Cannula
The iCAN trial is a pragmatic randomized controlled trial that aims to test the hypothesis that HFNC versus usual care oxygenation strategies applied immediately after initial extubation after cardiac surgery decreases the…
- Trial name
- NCT04782817
- Testing
- Recommendation for high flow nasal cannula oxygen therapy order set, Provider choice usual care order set
- Where
- United States
- Volunteers
- 3,568 people
- Sponsor
- Vanderbilt University Medical Center